MRNA Chart

1 Month

	Date	Diff
	2025-02-14	+3.35 %
Moderna (MRNA) stock rose by 3.35% despite a mixed fourth-quarter report showing higher-than-expected sales but greater-than-expected losses, likely due to positive market sentiment or investor optimism about future growth prospects after the earnings announcement. Moderna's stock (MRNA) rose 3.35% despite reporting another quarterly loss and facing challenges with waning vaccine sales and increased competition, as optimism may stem from the expectation of upcoming regulatory decisions on new vaccines and additional government funding for its bird flu vaccine development. Moderna (MRNA) stock rose 3.35% despite reporting a larger-than-expected fourth-quarter EPS loss and a significant decline in quarterly sales, likely due to investors reacting positively to the company's future prospects or other positive news overshadowing its recent financial performance. Moderna (MRNA) stock rose 3.35% despite reporting a fourth-quarter EPS loss of $(2.91) and significantly lower sales, as it managed to exceed revenue expectations, which may have fueled investor optimism. Moderna's (MRNA) stock rose by 3.35% after the company reported fourth-quarter sales that exceeded expectations despite a larger-than-expected net loss, partly due to significant cost reductions and the promising outlook for its pipeline of new mRNA products. Moderna (MRNA) stock rose by 3.35% due to positive sentiment surrounding potential upcoming developments, including new vaccine announcements or market expectations about its product pipeline, amidst broader market volatility.
	2025-02-13	+4.54 %
Moderna (MRNA) stock rose 4.54% in response to anticipation surrounding its upcoming quarterly earnings report expected on February 14, with analysts projecting a revenue of $951.09 million despite a forecasted loss per share of ($2.86). Moderna (MRNA) stock rose 4.54% likely due to positive market reactions to its upcoming earnings prospects, amid a backdrop of high volatility and performance in related sectors. The article discusses a comparison between Primo Brands and Fomento Económico Mexicano, highlighting their financial metrics and investment potential, but does not provide information on Moderna (MRNA) stock or its recent 4.54% increase; the rise in Moderna's stock could be attributed to factors such as positive market sentiment, favorable news regarding its products or financial performance, or overall trends in the biotech industry.
	2025-02-12	-1.28 %
Moderna (MRNA) stock decreased by 1.28% recently, partly due to analysts lowering their price targets and ratings for the company, indicating concerns about its financial outlook.
	2025-02-10	-2.24 %
Moderna (MRNA) stock fell by 2.24% as Janney Montgomery Scott LLC significantly reduced its holdings, coupled with several brokerages downgrading their price targets and ratings, indicating a lack of investor confidence. Moderna (MRNA) stock fell by 2.24% as investors appear to be underestimating the potential of promising drug candidates from competing pharmaceutical companies like Pfizer, despite strong earnings reports; Pfizer's recovery strategy and pipeline developments, along with broader industry concerns, contribute to investor skepticism affecting shares across the sector.
	2025-02-07	-3.01 %
The Moderna (MRNA) stock fell by 3.01% after the company announced its quarterly earnings, which included a modest profit but also highlighted ongoing challenges reflected in negative net margins and a poor return on equity. Moderna (MRNA) stock declined by 3.01% amid a focus on biotech stocks like AbbVie and Danaher, which might indicate investor sentiments shifting away from Moderna due to concerns about its market performance in a competitive biotech landscape.
	2025-02-05	+2.37 %
Moderna, Inc. (MRNA) stock rose 2.37% as institutional investors, including Tokio Marine Asset Management, significantly increased their holdings, indicating growing confidence in the company. The article discusses the potential implications of Jim O’Neill’s appointment as deputy secretary of Health and Human Services under Robert F. Kennedy Jr., suggesting that his deregulatory agenda may benefit biotechnology companies like Moderna, contributing to a recent 2.37% increase in Moderna's stock price due to anticipated easing of regulatory pathways for drug approvals. The article mentions that Moderna (MRNA) stock was up 2.37% last night, although the primary focus is on Globant (GLOB) and its recent price target changes by various analysts; specific reasons for Moderna's stock increase are not provided, but it could be attributed to positive market sentiment or recent developments in its business operations.
	2025-02-04	-6.51 %
Moderna (MRNA) stock fell by 6.51% following concerns over Robert F. Kennedy Jr.'s nomination for the Health and Human Services Department, which is viewed as a potential negative for vaccine manufacturers amidst ongoing political and regulatory shifts. Moderna (MRNA) stock fell by 6.51% following concerns about the nomination of Robert F. Kennedy Jr. to lead the Health and Human Services Department, which negatively impacted vaccine stocks amid potential regulatory implications. Moderna (MRNA) stock declined by 6.51% due to concerns arising from Robert F. Kennedy Jr.'s nomination for a key health position, which potentially signals regulatory changes that could impact vaccine-related companies. Moderna (MRNA) stock declined by 5.5% following the advancement of Robert F. Kennedy Jr. to a full Senate vote for the position of Secretary of Health and Human Services, leading to concerns about potential regulatory changes affecting vaccine policies. Moderna (MRNA) stock fell by 6.51% due to market reactions to broader concerns in the pharmaceutical sector, particularly the negative impact on sales forecasts following Merck's decision to halt shipments of its Gardasil vaccine to China, leading investors to worry about revenue growth and the overall health of vaccine-related stocks. Moderna's stock (MRNA) fell approximately 6% following a Senate panel's vote to advance the nomination of Robert F. Kennedy Jr., a well-known vaccine skeptic, to lead the Department of Health and Human Services, raising concerns about potential anti-vaccine rhetoric impacting public health initiatives.
	2025-01-31	-3.95 %
Moderna (MRNA) stock fell by 3.95% following a downgrade from Goldman Sachs, which changed its rating from "buy" to "neutral" and lowered the price target significantly from $99 to $51.
	2025-01-30	+0.79 %
The article discusses the contentious Senate hearings surrounding Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services, highlighting the influence of pharmaceutical industry donations on lawmakers and raising public health concerns, which, coupled with recent government financial support for Moderna, may have contributed to a 0.79% increase in Moderna's (MRNA) stock. Moderna's stock price increase can be attributed to the recent approval of funding from the Biden administration, amounting to $590 million, aimed at advancing efforts to combat H5N1, indicating ongoing government support for the company.
	2025-01-29	-9.39 %
Moderna (MRNA) stock experienced a 9.39% decline due to a combination of lowered price targets from analysts, investor sentiment reflected by changes in institutional holdings, and overall concerns about its financial performance, including a reported net margin of -43.77% and a projected negative earnings per share for the fiscal year. Moderna's stock (MRNA) dropped by 9.39% following Goldman Sachs' downgrade due to the company's second reduction in product revenue guidance within six months.
	2025-01-28	+7.9 %
Moderna (MRNA) stock surged 7.9% despite Evercore ISI reducing its price target from $60 to $50, likely due to the company's recent earnings report, which showed a profit that exceeded analyst expectations and a significant revenue increase.
	2025-01-24	-2.31 %
Moderna (MRNA) stock fell 2.31% despite securing a supply agreement for its COVID vaccines in Europe, likely due to market volatility or investor reactions to broader economic factors rather than the news itself. Moderna (MRNA) stock fell 2.31% due to concerns surrounding Robert F. Kennedy Jr.'s investments in biotech firms, particularly those involved in gene editing technologies he has criticized, which has raised skepticism among his supporters regarding the safety of mRNA vaccine development. Moderna (MRNA) stock fell by 2.31% last night, likely due to ongoing concerns regarding its future revenue after the initial COVID-19 vaccine sales have peaked, as well as broader market fluctuations affecting biotechnology stocks.
	2025-01-23	+10.1 %
Moderna (MRNA) stock increased by 10.1% due to a surge in call options trading, indicating heightened investor interest and positive sentiment following the company’s better-than-expected quarterly earnings report. The article discusses a comparison between Oncternal Therapeutics and Vertex Pharmaceuticals, focusing on institutional ownership, financial metrics, and stock performance, with Vertex showing stronger fundamentals but Oncternal having a higher potential upside in analyst target prices; notably, it doesn't directly address the recent 10.1% increase in Moderna (MRNA) stock. The increase in Moderna (MRNA) stock could be linked to various factors such as positive news related to their vaccine pipeline, favorable regulatory developments, or general market movements, but the specific reasons were not detailed in the provided article.
	2025-01-22	+7.27 %
Moderna, Inc. (NASDAQ: MRNA) saw a 7.27% increase in its stock value due to significant institutional investment activity, with major firms like Arkadios Wealth Advisors and State Street Corp increasing their positions, alongside positive quarterly earnings that exceeded expectations.
	2025-01-21	+5.37 %
Moderna Inc. (MRNA) stock rose 5.37% after the company announced continued support from the U.S. Department of Health and Human Services for the development of mRNA-based pandemic influenza vaccines, receiving a $590 million funding award to enhance clinical studies and accelerate the vaccine's development. Moderna (MRNA) stock rose 5.37% likely due to increased institutional investment interest, with significant stake increases reported from various large investors and positive adjustments in analyst ratings following the company’s better-than-expected earnings performance. Moderna (MRNA) stock rose 5.37% due to ongoing support from the U.S. Department of Health and Human Services for the development of mRNA-based pandemic solutions. Moderna (MRNA) stock rose 5.4% after the company announced it received $590 million in government awards for continued development of flu vaccines, contributing to a positive trend among stocks as many companies reported better-than-expected earnings. Moderna Inc (NASDAQ:MRNA) stock rose 5.37% due to ongoing support from the U.S. Department of Health and Human Services for the development of mRNA-based pandemic solutions, contributing to increased trading volume. Moderna (MRNA) stock rose by 6% after the company secured $590 million to expedite the development of its bird flu vaccine.
	2025-01-17	+0.89 %
Moderna (MRNA) stock rose by 0.89% after analysts from Leerink Partners issued their Q4 2025 earnings estimates, indicating potential growth despite overall negative earnings predictions, which may suggest investor confidence amid market fluctuations and positive performance in previous quarters. Moderna (MRNA) stock rose 0.89% due to a general market rally driven by positive inflation reports and strong earnings from major companies, despite Moderna itself having recently cut its future revenue outlook. The article discusses the impact of friction-free investing and rising trading frequency due to zero-fee platforms, highlighting the potential behavioral pitfalls for investors while noting that despite increased trading activity, most individuals typically fare better with index funds. Moderna (MRNA) stock rose 0.89% likely due to broader market optimism driven by cooler-than-expected inflation data in the US and UK, which positively influenced investor sentiment.
	2025-01-16	-2.9 %
Moderna (MRNA) stock fell by 2.9% due to declining interest and revenue expectations as the demand for its coronavirus vaccine has decreased significantly since the pandemic peak. Moderna (MRNA) stock has declined by approximately 79% since its peak last May, leading to a 2.9% drop last night, as investors question whether the stock represents a bargain amid ongoing concerns about its performance and future prospects. Moderna, Inc. (NASDAQ:MRNA) stock was down 2.9% as the company received lower earnings estimates from analysts and faced mixed ratings from various investment firms, indicating concern over its future performance.
	2025-01-14	-1.96 %
Moderna (MRNA) stock fell nearly 17% following a reduction in its 2025 revenue forecast by $1 billion, leading to further scrutiny and a technical breakdown from a two-month pennant pattern. Moderna (MRNA) stock dropped by nearly 17% after the company reduced its 2025 sales forecast by approximately $1 billion, anticipating revenues between $1.5 billion and $2.5 billion, primarily in the latter half of the year. Moderna (MRNA) stock fell by 1.96% after the company lowered its revenue forecast, which spooked investors amidst a backdrop of rising U.S. stock futures and inflation data.
	2025-01-13	-16.8 %
Moderna (MRNA) stock plummeted by 16.8% after the company lowered its 2025 sales forecast by $1 billion, now anticipating revenue between $1.5 billion and $2.5 billion. Moderna's stock fell over 17% due to the company lowering its revenue projections by $1 billion for 2025, citing weak demand for its COVID-19 vaccine and a slow rollout of its new RSV vaccine. Moderna (MRNA) stock fell 16% after the company reduced its 2025 sales forecast by $1 billion due to soft demand for its COVID-19 vaccines and slower adoption of its new respiratory syncytial virus (RSV) shot. Moderna (MRNA) stock fell by 16.8% after the company reduced its 2025 sales guidance by approximately $1 billion, citing potential challenges and a strategy to cut costs while broadening its product offerings. Moderna (MRNA) stock fell by 16.8% following the company's announcement of a $1 billion reduction in its 2025 sales guidance due to anticipated challenges and ongoing cost-cutting measures. Moderna (MRNA) stock plummeted 21.8% after the company reduced its sales forecast for 2025, amid a broader decline in global stock indexes influenced by strong US jobs data and concerns about interest rate cuts by the Federal Reserve. Moderna's (MRNA) stock dropped nearly 17% after the company lowered its 2025 sales guidance by approximately $1 billion, citing increased competition in the Covid vaccine market, falling vaccination rates, and uncertainties regarding manufacturing contracts and RSV revaccination recommendations.
	2025-01-10	-2.13 %
Moderna (MRNA) stock dropped 2.13% amidst a consensus recommendation of "Hold" from analysts and several brokerage firms adjusting their ratings and price targets downward. The decline may be attributed to lowered price targets and ratings from multiple brokerages, as well as insider selling, which likely raised concerns among investors. Moderna (MRNA) stock fell 2.13% after UBS Group lowered its price target from $108 to $96, indicating a lack of confidence in the stock's short-term performance amidst mixed analyst ratings and market concerns. The article discusses various investment opportunities and market trends as we approach 2025, highlighting that Moderna (MRNA) stock dropped 2.13% due to overall economic pressures and uncertainties in the healthcare sector, including competition and potential volatility in vaccine demand. Moderna (MRNA) stock fell by 2.13% amid a trend of declining analyst price targets and mixed institutional investor activity, with several funds increasing and decreasing their stakes in the company. Moderna (MRNA) stock fell 8.9% after UBS Group downgraded its price target from $108.00 to $96.00, indicating a decrease in investor confidence due to changing analyst ratings and expectations for the company's financial performance.
	2025-01-08	-9.17 %
Moderna (MRNA) stock plunged 9.17% amid mixed market reactions to concerns about economic policies proposed by President-elect Donald Trump, including the possibility of imposing tariffs, which could impact investor sentiment towards biotech stocks and raise inflation fears. Moderna (MRNA) stock experienced a significant drop of 9.17% following a notable rise in the previous days, which had been driven by optimism surrounding a bird flu death in the US; the decline suggests market volatility or investor profit-taking after recent gains. Moderna (MRNA) stock experienced a 9.17% decline following a mixed performance in the broader US stock market, as investors reacted to economic factors including uncertainty around tariffs proposed by President-elect Donald Trump and signals from the Federal Reserve regarding slower interest rate cuts, which raised concerns about future biotech funding and market sentiment. Moderna (MRNA) stock fell by 9.17% following heightened scrutiny on its bird flu vaccine development after the first reported bird flu death in the US, causing significant volatility in the stock's performance. Moderna (MRNA) stock saw a decline of 9.17% after initially experiencing a rise, due to market volatility and investor reaction following the reporting of the first bird flu death in the US, despite strong weekly performance expectations. Moderna's (MRNA) stock fell by 9.17% due to ongoing struggles with declining sales post-pandemic, including significantly reduced demand for its COVID-19 vaccine and disappointing revenue from its recently approved RSV vaccine. Moderna (MRNA) stock dropped 9.17% due to market volatility following the first known bird flu death in the US, which shifted focus to its vaccine development amid concerns about its declining revenue and future profitability. Moderna (MRNA) stock fell by 9.17% despite a strong economic backdrop and previously positive momentum, likely due to investor concerns about inflation and labor market challenges, influencing broader market sell-offs and speculation about the Federal Reserve's potential future rate adjustments.
	2025-01-07	+11.65 %
Moderna (MRNA) stock surged nearly 12% following the first reported bird flu death in the U.S. and news that the company received a $176 million government contract to develop its mRNA bird flu vaccine, coinciding with an uptick in COVID-19 cases. Moderna (MRNA) stock experienced an 11.65% increase, likely driven by positive earnings results exceeding analyst expectations, as well as recent changes in institutional investor positions and analyst ratings indicating mixed but generally cautious outlooks on the stock. Moderna (MRNA) stock surged nearly 12% due to the first reported bird flu death in the US and the subsequent government funding of $176 million for its development of an mRNA vaccine against the H5N1 virus. Moderna (MRNA) stock surged nearly 12% following the announcement of a significant government contract worth $176 million for the development of its mRNA H5N1 vaccine amidst rising concerns about bird flu and an uptick in COVID-19 cases in the U.S. Moderna (MRNA) stock surged 11.65% due to heightened concerns about avian flu, which increased demand for vaccine makers like Moderna, as healthcare stocks rose significantly amid broader market fluctuations. Moderna (MRNA) stock rose 11.65% due to increased investor interest following the report of the first bird flu death in the US, amid a backdrop of economic data raising inflation concerns that negatively impacted broader market indexes. Moderna's stock surged 14% to $48.56 per share after the U.S. reported its first human death from bird flu, prompting increased investor interest in the potential demand for mRNA-based vaccines to combat the virus. The stock rose due to the heightened focus on vaccine development in response to the bird flu concerns, particularly given Moderna's recent government contract to develop such a vaccine. Moderna's stock rose 11.65% after the CDC reported a two-week increase in positive Covid tests, signaling potential increased demand for Covid vaccines.
	2025-01-02	+1.01 %
Moderna (MRNA) stock rose by 1.01% last night, closing the year strong with a 5.59% increase as investors engaged in bargain-hunting, driven by perceived undervaluation despite persistent challenges and a 63.04% year-to-date decline due to reduced demand for COVID-19 vaccines.
	2024-12-31	+5.59 %
Moderna, Inc. (NASDAQ: MRNA) saw a 5.59% increase in its stock price, attributed to positive quarterly earnings that exceeded analysts' expectations, with the company reporting a profit of $0.03 per share against a forecast of a loss, and a significant increase in revenue compared to estimates.
	2024-12-27	-0.74 %
Moderna (MRNA) stock declined by 0.74% following unusually large put options trading, insider stock sales, and a negative shift in analyst ratings, which may signal reduced investor confidence in the company's future prospects.
	2024-12-26	+0.4 %
The article discusses the recent annual rebalancing of the Nasdaq-100 Index, highlighting how the addition of stocks like Moderna (MRNA) can lead to increased demand, contributing to a 0.4% rise in its stock price, as this change may shift sentiment toward the stock.
	2024-12-23	+0.51 %
The article discusses the recent inclusion of MicroStrategy (MSTR), along with Palantir Technologies (PLTR) and Axon Enterprise (AXON), into the Nasdaq-100 index, leading to a modest rise in Moderna (MRNA) stock, which is set to be replaced by these companies. Moderna's stock may have gone up due to investor sentiment reacting to positive broader market movements and the anticipated influx of buying from index funds following the Nasdaq-100 reconstitution, although it is being removed from the index.
	2024-12-20	-0.43 %
Moderna (MRNA) stock fell by 0.43% due to being removed from the Nasdaq-100 index during a quarterly rebalancing, which affects investor confidence and trading in index-based exchange-traded funds (ETFs). Moderna (MRNA) stock experienced a decline of -0.43% last night, likely influenced by broader market trends and investor sentiment toward biotech stocks, as the company may face ongoing challenges in its vaccine sales and product pipeline.
	2024-12-19	+3.13 %
Moderna (MRNA) stock rose by 3.13% due to a combination of market dynamics, including investor interest in merger and acquisition activity despite concerns about tariffs and inflation, as discussed by Jim Cramer in his recent commentary. Moderna (MRNA) stock rose 3.13% after the company reported better-than-expected quarterly earnings, significantly exceeding analyst expectations for both earnings per share and revenue, despite some institutional investors adjusting their stakes in the company.
	2024-12-18	-5.89 %
Moderna (MRNA) stock fell by 5.89% due to its upcoming removal from the Nasdaq-100 index, as it will be replaced by MicroStrategy, which is set to enter the index alongside other companies.
	2024-12-17	-2.58 %
Moderna (MRNA) stock experienced a decline of 2.58% amidst a broader market downturn affected by concerns over high valuations in tech stocks like Nvidia and potential changes in Federal Reserve interest rate decisions. The stock went down due to overall market volatility and investor sentiment shifting away from riskier assets, particularly in the tech sector.
	2024-12-16	+0.02 %
The article discusses the recent struggles of Super Micro Computer (SMCI), which is experiencing a significant decline in stock value after being removed from the Nasdaq-100 Index, while Moderna (MRNA) stock saw a slight 0.02% increase, likely due to its replacement in the index and potential renewed investor interest in more stable companies amidst the turmoil affecting SMCI. Moderna's (MRNA) stock experienced a slight increase of 0.02% amid a mixed week for the stock market, influenced by a surge in Bitcoin prices and upcoming changes to the Nasdaq 100 Index that will exclude Moderna, which may have prompted investors to reposition their portfolios. The increase in Moderna's stock can be attributed to broader market trends and investor behavior rather than specific news regarding the company itself. The article discusses how MicroStrategy's inclusion in the Nasdaq-100 Index, effective December 23, has driven up the stock price due to investor interest and the expected buying by index-tracking funds, with Moderna (MRNA) stock increasing slightly by 0.02% likely due to market sentiment and broader stock market movements despite its removal from the index. Moderna (MRNA) stock saw a slight increase of 0.02% amidst a mixed analyst outlook, with an average rating of "Hold" from twenty-one analysts and various price target changes reflecting the company's recent earnings performance, which exceeded expectations. The stock's rise may be attributed to the company's reported quarterly earnings that surpassed analysts' estimates, showing profitability and revenue growth, as well as the ongoing interest from institutional investors. The article discusses the recent movement of MicroStrategy's stock which briefly surged before closing lower, as the company was selected to join the tech-heavy Nasdaq 100 index, increasing its indirect exposure to bitcoin and potentially attracting additional investment. Moderna (MRNA) stock went up because of overall positive market momentum, likely related to MicroStrategy's association with the Nasdaq 100, which may have influenced investor sentiment across biotech and tech sectors. The article highlights that Moderna (MRNA) stock rose by 0.02% last night, likely due to its stability and continued investor confidence despite being removed from the Nasdaq 100 index, which suggests a shift in market dynamics rather than a negative outlook for the company itself. Moderna (MRNA) stock saw a slight increase of 0.02%, attributed to its strong balance sheet with over $6 billion in cash, indicating potential for development of new drugs despite the company's significant decline in stock value since the pandemic. Moderna (MRNA) stock saw a slight increase of 0.02% despite being removed from the Nasdaq-100 Index due to a significant decline of over 60% year to date, reflecting investor reactions to its ongoing performance and market adjustments. The stock likely went up due to a combination of market fluctuations or transient investor sentiments following the news.
	2024-12-13	-2.31 %
Moderna (MRNA) stock fell 2.31% after Bank of America maintained its underperform rating and set a price target of $41, amidst a series of downgrades from multiple analysts.
	2024-12-12	-0.09 %
Moderna (MRNA) stock fell by 0.09% following public comments by Robert F. Kennedy Jr., a nominee for head of the Department of Health and Human Services, who expressed criticism of GLP-1 weight loss drugs and raised concerns about their impact on public health and pharmaceutical companies, which negatively influenced investor sentiment towards Moderna and other vaccine-related stocks. Moderna (MRNA) stock fell by 0.09% despite increased institutional investment and positive earnings results due to declining analysts' price targets and overall bearish sentiment in the market, prompting concerns about its valuation and future growth.
	2024-12-10	-9.07 %
Moderna (MRNA) stock fell by 9.07% largely due to a mix of cautious analyst ratings, with many firms downgrading their price targets and outlooks for the company, as well as insider selling that may have contributed to negative sentiment around the stock.
	2024-12-06	+3.49 %
The article discusses the low uptake of the updated COVID-19 vaccine in the U.S. and potential factors influencing Moderna (MRNA) stock, which rose by 3.49%, likely due to ongoing interest in mRNA vaccines amid fears of winter outbreaks and the company's positioning as a leading player in vaccine supply. Moderna (MRNA) stock rose 3.49% due to increased institutional investment, as several hedge funds expanded their stakes in the company, contributing to positive investor sentiment despite mixed analyst ratings. Moderna (MRNA) stock rose by 3.49% due to increased investments from institutional investors, which signaled confidence in the company's performance, as well as recent stronger-than-expected earnings and revenue reports compared to analyst estimates. Moderna's stock (MRNA) rose by 3.49% following a significant increase in institutional investment, including large purchases from several investors during the third quarter, indicating strong market confidence in the company's future potential.
	2024-11-29	-0.76 %
Moderna (MRNA) stock fell by 0.76% following a reduction in its price target from $59.00 to $45.00 by JPMorgan Chase & Co., which also issued an underweight rating for the stock. The decline in Moderna's stock price is attributed to analysts reducing their price targets and ratings for the company, reflecting a lack of confidence in its future performance.
	2024-11-27	+3.19 %
Moderna (MRNA) stock rose by 3.19% following optimistic projections about its future sales, particularly from upcoming vaccines, despite facing challenges in the market. The increase in Moderna's stock can be attributed to positive market sentiment regarding the anticipated rollout of its RSV vaccine and strong feedback from regulatory bodies, along with expected sales growth and partnership developments.
	2024-11-26	-3.69 %
Moderna (MRNA) stock fell by 3.69% due to a combination of broader market pressures, reduced price targets from analysts, and insider selling. Moderna's (MRNA) stock fell by 3.69% due to investor concerns over uncertainties in regulatory environments and potential impacts on vaccine demand and pricing, as well as broader economic factors affecting market sentiment.
	2024-11-25	+6.2 %
Moderna (MRNA) stock recently rose by 6.2%, likely driven by investor optimism associated with the "January Bounce" phenomenon, which sees stocks that have struggled in previous months rebound as tax-motivated selling eases. The article discusses class action lawsuits filed against various companies, including Metagenomi, Inc., due to misleading statements affecting their business prospects, and mentions that Moderna (MRNA) stock rose by 6.2%, likely related to the perception of its ongoing collaborations and overall market confidence in the biotech sector. The article discusses a class action lawsuit involving several companies, including Moderna, and reports that Moderna (MRNA) stock rose 6.2% following a legal reminder for investors regarding their rights in the lawsuit. The increase in Moderna's stock can be attributed to positive market sentiment or investor confidence that may have been sparked by the lawsuit details, although the article primarily focuses on other companies and their allegations rather than providing a definitive reason for Moderna's stock movement.
	2024-11-22	+7.48 %
Moderna (MRNA) stock increased by 7.48% due to significant institutional investment activity, including a new stake bought by GSA Capital Partners and increases in holdings by other large investors, despite a mixed performance in earnings and analysts' ratings. Moderna (MRNA) stock rose 7.48% following HSBC Global Research's upgrade from a hold to a strong-buy rating, reflecting increased confidence in the company's potential for growth amidst positive earnings results that exceeded analysts' expectations. Moderna (MRNA) stock rose by 7.48% despite analysts lowering their FY2025 EPS estimates, likely due to a combination of better-than-expected recent earnings and a positive outlook from some analysts, including upgrades from HSBC Global and Deutsche Bank, which contributed to renewed investor interest.
	2024-11-21	+3.55 %
The article discusses Joe Rogan's criticisms of Bill Gates regarding his role in the COVID-19 pandemic and vaccine promotion, claiming that Gates is responsible for people taking unproven medications, while the Moderna (MRNA) stock rose by 3.55%, likely due to a positive perception of vaccine effectiveness amid ongoing discussions about COVID treatment and vaccine strategies. Moderna (MRNA) stock increased by 3.55% possibly due to a positive quarterly earnings report that showed better-than-expected EPS and revenue, alongside continued interest from institutional investors. Moderna (MRNA) stock rose by 3.55% due to an upgrade from HSBC, which changed its rating from "hold" to "buy" and set a new price objective of $58.00, amidst a generally mixed consensus rating among analysts. Moderna (MRNA) stock rose 3.55% following Berenberg Bank's report initiating coverage with a "hold" rating and a $42 price target, indicating potential upside, along with positive quarterly earnings that exceeded expectations. Moderna (MRNA) stock rose 3.55% likely due to positive investor sentiment in the wake of a class action lawsuit involving its former collaborator, Metagenomi, suggesting confidence in Moderna's stability amid external controversies.
	2024-11-20	-0.94 %
The article discusses a lawsuit related to Metagenomi, Inc. (MGX), which is tied to a terminated collaboration with Moderna (MRNA) that negatively impacted Metagenomi's stock price, causing concerns that likely contributed to a decline in Moderna's stock by 0.94%. Moderna (MRNA) stock, along with other health stocks, experienced a decline of -0.94% due to investor concerns about the potential impact of Robert F. Kennedy Jr.'s nomination as head of the Department of Health and Human Services, particularly regarding his vocal skepticism of vaccines and health policies that may affect the pharmaceutical sector.
	2024-11-19	-5.62 %
Moderna (MRNA) stock declined by 5.62% due to broader market trends affecting healthcare stocks and investor sentiment following mixed earnings performance from related companies, such as Medtronic, which faced supplier issues despite reporting better-than-expected revenue. Moderna (MRNA) stock fell by -5.62% after Wolfe Research initiated coverage with an underperform rating and a $40 price target, amid a series of negative adjustments to price targets and ratings from other analysts. Moderna (MRNA) stock fell by 5.62% after Huntington National Bank reported reducing its holdings in the company by nearly a third, combined with negative sentiment from several analysts downgrading their ratings and lowering price targets for the stock. Moderna (MRNA) stock fell 5.62% following news of the termination of its collaboration with Metagenomi, which was revealed in a class action lawsuit alleging misleading statements by Metagenomi's management regarding the partnership's future. Moderna (MRNA) stock fell 5.62% due to concerns raised after President-elect Donald Trump nominated vaccine skeptic Robert F. Kennedy Jr. as Health and Human Services secretary, which negatively impacted vaccine manufacturer stocks. Additionally, finance departments are increasingly planning to use AI for greater efficiency, potentially leading to reduced workforce needs, while investors are adjusting their expectations following recent economic signals and election outcomes. Moderna (MRNA) stock fell by 5.62% due to concerns surrounding the nomination of Robert F. Kennedy Jr., a prominent anti-vaccine activist, to lead the Department of Health and Human Services under Trump's new administration. The article discusses a class action lawsuit against Metagenomi, Inc. following the termination of its collaboration with Moderna, which has likely contributed to a decline in Moderna’s stock price by 5.62%. Moderna's stock decline is attributed to the negative market reaction to the termination of the collaboration agreement with Metagenomi, raising concerns over its business prospects. The article discusses the decline of Moderna (MRNA) stock by -5.62%, which may be attributed to concerns over the company’s future revenue prospects as it faces pressure from competitors and shifts in vaccine demand. The article discusses the decline of Moderna (MRNA) stock by 5.62%, attributing part of the decrease to the termination of its collaboration agreement with Metagenomi, which was a crucial aspect of Metagenomi's business model and likely raised concerns among investors about future prospects.
	2024-11-18	+7.22 %
Moderna (MRNA) stock increased by 7.22% last night, likely driven by positive investor sentiment following the recent results of the U.S. presidential election that may have boosted market confidence in pharmaceutical companies amid regulatory shifts. Moderna's stock rise can be attributed to investor optimism regarding the potential impacts of the incoming Republican government, which is often perceived as more favorable to pharmaceutical and vaccine-related businesses, despite some initial concerns after Trump's controversial cabinet pick related to health policies. The article discusses a class action securities lawsuit against Metagenomi, Inc., which may have positively impacted Moderna (MRNA) stock by increasing investor interest in companies associated with biotechnology collaborations, leading to a 7.22% rise in its stock price. Moderna (MRNA) stocks were up 1.3% amidst overall market caution following the volatility after President Trump's election, influenced by investor sentiment regarding potential economic policies and the recent appointment of a vaccine skeptic to a health role, which has caused fluctuations in vaccine-related stocks. The increase in Moderna's stock is likely reflective of investor optimism, despite the broader market uncertainties. Moderna (MRNA) stock increased by 7.22% following positive investor sentiment and potential announcements about its future products, leading to market optimism about its financial performance and growth prospects. The article discusses Donald Trump's plans for his second term, focusing on significant reductions in government agencies under the guidance of his appointed co-chair Vivek Ramaswamy, who proposes sweeping changes to the executive branch, potentially leading to mass budget cuts and the removal of certain government entities. Modern (MRNA) stock likely rose by 7.22% last night due to market reactions to political developments and potential changes in government policies that could affect the biotech sector, along with investor optimism around the company's future prospects amidst Trump's administration's emphasis on efficiency and budget management. Moderna (MRNA) stock rose by 7.22% likely due to positive developments or investor sentiment surrounding its ongoing vaccine and therapeutic advancements, although specifics about the catalyst for this increase are not detailed in the article provided. Moderna's (MRNA) stock rose 7.22% as part of a broader recovery in U.S. stocks following a sharp decline, likely boosted by investors reassessing the potential economic impacts of Trump's presidential policies, despite previous concerns about his anti-vaccine stance. Moderna (MRNA) stock rose 7.2% on a day when most U.S. stocks showed a recovery from previous declines, as investors reacted to broader market dynamics influenced by political events and economic indicators, despite ongoing concerns about appointment of Robert F. Kennedy Jr. as head of the Department of Health and Human Services, a potential negative for vaccine manufacturers. Moderna's stock (MRNA) rose by 7.22% after experiencing a decline earlier in the week, primarily due to investor reactions to Donald Trump's announcement of Robert F. Kennedy Jr. leading Health and Human Services, which raised concerns about potential vaccine bans and could impact future vaccine market dynamics.
	2024-11-15	-7.34 %
Moderna (MRNA) stock fell by 7.34% after investors reacted negatively to Donald Trump's nomination of vaccine critic Robert F. Kennedy Jr., raising concerns about the potential impact on major pharmaceutical companies engaged in vaccine development. Moderna (MRNA) stock dropped 7.34% primarily due to the appointment of Robert F. Kennedy Jr., a noted vaccine skeptic, as the head of the Department of Health and Human Services by President-elect Donald Trump, which negatively impacted shares linked to vaccine developers. Moderna's (MRNA) stock fell 7.34% amid broader market declines, primarily due to concerns over potential profit impacts following President-elect Donald Trump's consideration of appointing anti-vaccine activist Robert F. Kennedy Jr. to lead the Department of Health and Human Services, creating uncertainty for investors in the vaccine sector. Moderna's stock (MRNA) fell by 7.34% due to concerns triggered by Donald Trump appointing vaccine skeptic Robert F. Kennedy Jr. as head of the Department of Health and Human Services, leading investors to fear potential negative impacts on the pharmaceutical industry. Moderna's (MRNA) stock fell by 7.34% after worries arose from Donald Trump's nomination of Robert F. Kennedy Jr., a vaccine skeptic, to lead the Department of Health and Human Services, which negatively affected the shares of major pharmaceutical companies. Moderna (MRNA) stock fell 7.34% due to concerns about potential profit impacts following President-elect Trump's nomination of Robert F. Kennedy Jr., an antivaccine activist, to lead the Department of Health and Human Services, leading to broader declines in the vaccine and biotech sectors. Moderna (MRNA) stock fell 7.34% as part of a broader market decline influenced by Federal Reserve Chair Jerome Powell's hawkish stance on interest rates, combined with negative sentiment in the healthcare sector following President-elect Donald Trump's appointment of Robert F. Kennedy Jr. as head of Health and Human Services, raising concerns about future vaccine policy. Moderna (MRNA) stock dropped by 7.34% following Donald Trump's controversial appointment of vaccine opponent Robert F. Kennedy Jr. as the Secretary of Health and Human Services, which caused concern among investors about the potential negative impact on the pharmaceutical industry and public health policies.
	2024-11-14	-5.62 %
Moderna (MRNA) stock fell by more than 5% following the nomination of vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services by President-elect Donald Trump, which raised concerns about potential anti-vaccine rhetoric that could impact vaccination rates and, consequently, profits for vaccine manufacturers. Moderna (MRNA) stock dropped over 5% after reports surfaced that President-elect Donald Trump nominated vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services, raising concerns about increased anti-vaccine sentiment that could negatively impact vaccination rates and the companies' future profits. Moderna (MRNA) stock fell by 5.62% due to investor concerns following reports that President-elect Trump plans to appoint anti-vaccine activist Robert F. Kennedy Jr. as head of the Department of Health and Human Services, which raised fears about potential impacts on the vaccine industry. Moderna's stock fell over 5% due to market fears regarding decreased future vaccine demand following Robert F. Kennedy Jr.'s appointment as head of HHS, as his anti-vaccine stance may deepen public skepticism and reduce vaccination rates.
	2024-11-12	+1.68 %
The Rosen Law Firm announced a class action lawsuit concerning Metagenomi, Inc.’s IPO, highlighting a critical deadline for investors, while Moderna (MRNA) stock rose by 1.68% following the news of its past collaboration termination with Metagenomi, indicating market confidence or speculative interest. Moderna's stock increase could be attributed to investor sentiment surrounding the company's performance and potential future advancements following the cessation of its partnership with Metagenomi. Moderna (MRNA) stock rose by 1.68% due to positive earnings results that significantly exceeded analysts' expectations, with the company reporting a profit of $0.03 per share and $1.90 billion in revenue, compared to forecasts of a loss and lower revenue estimates.
	2024-11-07	-2.95 %
Moderna (MRNA) stock declined by 2.95% as part of a broader market response to Donald Trump's election win, which has raised concerns about potential inflationary pressures and tariffs that could negatively impact pharmaceutical stocks like Moderna. Moderna (MRNA) stock declined by 2.95% as investors reacted to the termination of the collaboration agreement between Moderna and Metagenomi, which raised concerns about Metagenomi's future prospects and affected its stock performance. Moderna's stock initially rose 5% following strong third-quarter earnings, but subsequently fell 2.95%, likely due to profit-taking or market volatility after the gains. Moderna (MRNA) stock fell by 2.95% despite beating third-quarter expectations, primarily due to concerns over decreasing sales of its respiratory syncytial virus (RSV) vaccine and maintaining a cautious outlook for future sales driven largely by Covid vaccine sales. Moderna (MRNA) stock fell by 2.95% amid a tech-led market rally predominantly influenced by a Federal Reserve interest rate cut and investor enthusiasm surrounding economic prospects following Donald Trump's election victory, which may have shifted focus away from biotech stocks like Moderna. Moderna (MRNA) stock fell 2.95% amid a broader market rally driven by a Federal Reserve interest rate cut and optimism surrounding Donald Trump's presidential election victory, which favored tech and financial stocks, overshadowing any gains for biotechnology shares like Moderna. Moderna (MRNA) stock fell 2.95% likely due to broader market volatility and investor concerns about inflation and government policies following the recent U.S. election.
	2024-11-06	-2.78 %
Moderna (MRNA) stock dropped 2.78% in value as it approaches the announcement of its earnings results, with analysts expecting a loss of $1.93 per share, reflecting investor apprehension and reduced price targets from several analysts. The article discusses Arbutus Biopharma Corporation's recent developments in clinical trials and financial results, indicating a cash runway into 2026 and ongoing litigation related to its patent technology used by Moderna and Pfizer/BioNTech. The decline of Moderna's (MRNA) stock by -2.78% may be attributed to the ongoing litigation and claims from Arbutus regarding the use of its patented LNP technology, which could raise concerns about potential financial liabilities and impact future profitability.
	2024-11-05	-0.47 %
The article discusses a recent class action lawsuit against Metagenomi, Inc. that highlights misleading statements regarding its collaboration with Moderna, which may have contributed to the 0.47% decline in Moderna's stock (MRNA). The drop in Moderna's stock could be attributed to concerns surrounding the termination of collaboration with Metagenomi, leading to uncertainty about the company's future prospects and investor sentiment.
	2024-11-04	-2 %
Moderna (MRNA) stock declined by 2.0% following the termination of its collaboration agreement with Metagenomi, which raised concerns about the viability of Metagenomi's business model and negatively impacted investor confidence. Moderna (MRNA) stock fell by 2.0% possibly due to Nisa Investment Advisors LLC significantly reducing its stake in the company by 81%, and analysts' downgrades of the stock's price targets, reflecting bearish sentiment among investors.
	2024-11-01	+0.5 %
Moderna's stock (MRNA) was up 0.5% as institutional investors adjusted their holdings, with some increasing their positions, amid varied analyst ratings and strategic reviews of the company's stock, which reflects overall market interest despite a challenging revenue environment.
	2024-10-31	-0.66 %
Moderna (MRNA) stock decreased by 0.66% due to broader market trends and possibly negative investor sentiment, although the article primarily discusses Microsoft and does not provide specific reasons for Moderna's decline. The article discusses the recent turmoil at 23andMe following the abrupt resignation of its board members and the appointment of new finance-focused directors, while also noting a decline in Moderna (MRNA) stock by 0.66%. Moderna's stock may have fallen due to ongoing market fluctuations and broader concerns in the biotech sector, which affects investor confidence in the company's future performance. Moderna (MRNA) stock declined by 0.66% due to a combination of institutional investors reducing their stakes, analysts lowering price targets and ratings, and insider selling activity, indicating potential waning confidence in the company's future performance. The article discusses a decline in Moderna (MRNA) stock, which fell by 0.66%, primarily due to the termination of its collaboration agreement with Metagenomi, a critical aspect of their partnership that raised concerns about the future of both companies. Moderna (MRNA) stock declined by 0.66% amid concerns related to its collaboration with Metagenomi, Inc., which was terminated earlier this year, leading to investor lawsuits and uncertainty about future earnings.
	2024-10-30	-0.91 %
Moderna (MRNA) stock fell by 0.91% after the company reported a quarterly loss with negative earnings per share and a decline in revenue compared to the previous year, despite some institutional investors increasing their stakes. Moderna (MRNA) stock fell by 0.91% as analysts reduced their target prices for the company amid concerns over its recent financial performance, including a negative EPS and declining revenue. The article discusses various class action lawsuits against multiple companies, but it specifically mentions that Moderna's stock (MRNA) was down by 0.91% possibly due to investor concerns surrounding misleading statements from companies associated with it, including Metagenomi, which claimed a strategic collaboration with Moderna, thereby impacting investor trust in related entities. The article discusses the urgent need for preparations against a potential H5N1 bird flu pandemic, highlighting the inadequacy of current vaccine stockpiles and the challenges of rapid vaccine development, particularly regarding Moderna's mRNA vaccine for H5N1, which may have contributed to a -0.91% drop in its stock as concerns about preparedness and public acceptance of vaccines linger.
	2024-10-29	+0.77 %
Moderna (MRNA) stock rose by 3.9% due to positive investor sentiment and market conditions following recent developments or announcements related to the company. Moderna (MRNA) stock increased by 0.77% due to Raymond James & Associates boosting its holdings in the company by 19.7% in the third quarter, acquiring an additional 26,657 shares. The article reports that Moderna (MRNA) stock rose by 0.77% amidst ongoing class action lawsuits involving other companies, particularly highlighting that the allegations against Metagenomi, regarding their collaboration with Moderna, could reflect positively on Moderna’s standing. The increase in Moderna's stock price might be attributed to investors reacting favorably to news about its collaborations or general performance stability, despite the negative press surrounding associated companies.
	2024-10-28	+3.22 %
The article discusses Metagenomi's class action lawsuit linked to its IPO and the termination of its collaboration with Moderna, which negatively impacted Metagenomi's stock but does not directly address the reasons behind Moderna's stock increase of 3.22%; however, it can be inferred that Moderna may have experienced a rise in investor confidence after distancing itself from Metagenomi's issues. Moderna's stock (MRNA) rose 3.22% following the announcement of a pivotal Phase 3 trial, INTerpath-009, for their investigational therapy V940 in combination with Merck's Keytruda, indicating investor optimism about the potential success and impact of this treatment. Moderna (MRNA) stock rose 3.22% following the announcement of the initiation of a pivotal Phase 3 trial for its investigational therapy V940, in combination with Merck's Keytruda, which has generated investor optimism regarding its potential.
	2024-10-24	-1.11 %
Moderna (MRNA) stock fell by 1.11% due to concerns stemming from a class action lawsuit alleging that Metagenomi's collaboration with Moderna would not continue, which could impact investor confidence in Moderna's business prospects. Moderna (MRNA) shares experienced a decline of 1.11%, with analysts mostly recommending a "Hold" rating, indicating a lack of strong bullish sentiment that may contribute to the stock's decrease. Moderna (MRNA) stock fell by 1.11% after UBS Group reduced its price target from $140.00 to $108.00 while maintaining a "buy" rating, indicating potential concerns about the company's outlook or performance. The Moderna (MRNA) stock fell by -1.11% as a result of investor concerns stemming from the termination of its collaboration agreement with Metagenomi, which was previously highlighted during Metagenomi's initial public offering.
	2024-10-23	-0.02 %
The article discusses a notice from The Gross Law Firm alerting shareholders of Metagenomi, Inc. about a class action related to the termination of a collaboration agreement with Moderna, which has negatively influenced Metagenomi's stock price and may indirectly impact Moderna's stock, contributing to a slight decline of -0.02% in Moderna (MRNA) stock. Moderna's stock likely went down due to investor concerns stemming from the unexpected termination of the strategic partnership with Metagenomi, which raised uncertainties about their future collaboration and potential impacts on both companies. Moderna (MRNA) stock saw a slight decline of -0.02% due to concerns stemming from a terminated collaboration agreement with Metagenomi, which has led to uncertainty regarding future partnerships and developments. Moderna (MRNA) stock decreased by 0.02% recently, primarily due to insider selling by the CFO and modest adjustments in institutional holdings amid a generally cautious market sentiment reflected in various analysts' ratings.
	2024-10-22	-0.74 %
Moderna (MRNA) stock declined by 0.74% following news of the termination of its collaboration with Metagenomi, contributing to concerns over the company's future prospects highlighted in a related class action lawsuit.
	2024-10-21	-0.55 %
Moderna (MRNA) stock was down 0.55% likely due to investor concerns regarding the upcoming 2024 U.S. presidential election, which may shift focus and market sentiment towards other sectors and stocks benefiting from the policies of either potential winner, rather than biotech and pharmaceuticals where Moderna operates. The article discusses a class action lawsuit against Metagenomi, Inc. following the termination of its collaboration agreement with Moderna, which negatively affected investor confidence in the company and its stock price. Moderna (MRNA) stock may have declined due to its association with Metagenomi's fallout, as investors reacted to the news of the terminated deal and potential impacts on future collaborations and revenues. Moderna (MRNA) stock experienced a decline of 0.55% likely due to increased fear and misinformation surrounding vaccine safety, particularly related to the long-debunked claims about contamination and health risks associated with vaccine ingredients, which have gained traction among antivaccine groups.
	2024-10-18	-1.31 %
Moderna (MRNA) stock declined by 1.31% amid a generally positive market performance with key indices setting new records and strong earnings reports from companies like Netflix overshadowing its performance, possibly reflecting investor concerns about the broader market dynamics and sentiment rather than specific issues with Moderna. Moderna (MRNA) stock recently declined by 1.31%, likely due to increased competition and market shifts affecting investor sentiment following its significant gains during the pandemic. Moderna (MRNA) stock declined by 1.31% following news of a terminated collaboration with Metagenomi, which was initially touted as a significant partnership during Metagenomi's IPO. Moderna's stock (MRNA) declined by 1.31% despite Vontobel Holding Ltd. significantly increasing its stake in the company by 148.2% in the third quarter, indicating a potential disconnect between institutional investment and market performance. The drop in Moderna's stock may be attributed to broader market trends, company-specific news, or investor sentiment rather than the increase in institutional holdings. Moderna (MRNA) stock fell by 1.31% due to concerns arising from a class action lawsuit related to a collaboration with Metagenomi, Inc., which allegedly misled investors about the future of their partnership. Moderna (MRNA) stock fell by 1.31% due to increased activity in put options, suggesting bearish sentiment among investors, highlighting concerns about the company's financial performance despite a recent positive earnings report that beat estimates but showed significant revenue decline. Moderna (MRNA) stock fell by 1.31% following news that SeaCrest Wealth Management LLC reduced its stake in the company by 9.6%, amidst mixed analyst ratings and target price adjustments reflecting cautious sentiment regarding the company's future performance. The decline in Moderna's stock can be attributed to several factors, including SeaCrest's reduction of their position, analyst downgrades and lowered price targets from various financial institutions, as well as the company's ongoing struggles with revenue and profitability. Moderna (MRNA) stock fell by 1.31% following a downgrade of its Q3 2024 earnings per share estimates by Zacks Research, which revised the expected loss from ($1.83) to ($1.88) per share, contributing to a negative sentiment around the company's financial outlook.
	2024-10-17	-4.59 %
Moderna (MRNA) stock fell by 4.59% following a news event related to Metagenomi, which announced the termination of its collaboration with Moderna, leading to investor concerns over potential impacts on Moderna's business. Moderna (MRNA) stock declined by 4.59% last night, despite Exchange Traded Concepts LLC significantly increasing its stake in the company by 164.0% in the 3rd quarter; the decline could be attributed to market fluctuations or investor sentiment rather than the institutional investment. Moderna (MRNA) stock fell by 4.59%, possibly due to intensified competition and market volatility, particularly as investors evaluate performance relative to peers like GSK and Merck, which may have impacted investor confidence in Moderna's growth prospects.
	2024-10-16	+0.26 %
The article discusses the legal notice issued by The Gross Law Firm regarding a class action lawsuit for shareholders of Metagenomi, Inc., related to the termination of its collaboration with Moderna, which affected Metagenomi's stock price but also coincided with a slight increase in Moderna (MRNA) stock by 0.26%. Moderna's stock may have gone up due to market reactions to potential developments or positive sentiment around their ongoing projects, despite the setback faced by Metagenomi following the termination of its collaboration with Moderna. Moderna (MRNA) stock rose by 0.26% amid various analyst ratings, including a hold rating from Jefferies and upgrades from HSBC and Deutsche Bank, reflecting a mixed but generally stable outlook for the company despite price target reductions. Moderna's stock increase may result from positive earnings that surpassed analyst expectations and ongoing interest from institutional investors, indicating a level of confidence in the company's future prospects. The article reports that Moderna's stock (MRNA) saw a slight increase of 0.26%, following news about a class action lawsuit involving Metagenomi Inc., which allegedly misled investors regarding its collaboration with Moderna. This rise in Moderna's stock may be attributed to investor sentiment regarding the potential implications of Metagenomi's legal troubles, reflecting a perception of stability or confidence in Moderna amidst the scrutiny faced by its former partner. Moderna (MRNA) stock rose by 0.26% in the wake of Novavax's setback with its vaccine development, suggesting that investors may view Moderna more favorably as an established player in the mRNA vaccine space amidst declining competition. The article discusses an investigation into Metagenomi, Inc. by the law firm Faruqi & Faruqi LLP due to potential legal claims related to false statements about its collaboration with Moderna, following the termination of their agreement, which led to Metagenomi's stock price decline. Moderna (MRNA) stock might be up due to market reactions to broader industry dynamics or investor sentiment possibly benefiting from the ongoing developments in the biotech sector, despite specific issues surrounding Metagenomi.
	2024-10-15	-0.73 %
Moderna (MRNA) stock declined by 0.73% due to a combination of lower-than-expected quarterly results, reduced price targets from several analysts, and ongoing insider share sales, which may signal lack of confidence from company executives.
	2024-10-14	-0.96 %
The article reports on the recent performance of various stocks, noting that Moderna (MRNA) stock fell by 0.96%, attributed to Ark Invest's decision to sell over 100,000 shares amid its significant underperformance, which saw it decline over 41% this year in contrast to the generally strong markets and other tech stocks making gains. Moderna (MRNA) stock decreased by 0.96% following news of a class action securities lawsuit against Metagenomi, which highlighted the termination of a crucial collaboration between the two companies that adversely affected investor confidence in Metagenomi's future performance and, by extension, impacted Moderna's stock. Moderna (MRNA) stock experienced a decline of 0.96% as Polianta Ltd disclosed its new purchase of 12,500 shares, highlighting ongoing market reactions to institutional investment movements rather than a specific negative catalyst for the drop.
	2024-10-11	+2.57 %
The article discusses a class action lawsuit targeting Metagenomi, Inc. and highlights the financial implications for investors following the termination of its collaboration agreement with Moderna, which could contribute to Moderna's stock price increase by signaling stability and independence from potential negative impacts associated with the lawsuit. Moderna's stock may have gone up due to investor confidence stemming from the clarified separation from Metagenomi after the lawsuit, suggesting that the market views Moderna as less exposed to incoming legal challenges related to the IPO of Metagenomi. The article discusses a potential securities class action against Metagenomi following the termination of its collaboration with Moderna, while Moderna's stock (MRNA) rose by 2.57% potentially due to investor confidence in the company's ongoing business amidst challenges faced by its partner. Moderna (MRNA) stock rose 2.57% last night, largely due to increased institutional investment, including a 7.3% stake increase by Truist Financial Corp, which signals growing confidence in the company's potential despite recent financial challenges. The article discusses class action lawsuits filed on behalf of shareholders of various companies, including Metagenomi, which disclosed that a collaboration with Moderna would end sooner than expected, potentially affecting investor sentiment. Moderna's (MRNA) stock increased by 2.57% possibly due to investor optimism surrounding its ongoing developments or reassessment of its market position despite the lawsuit news. The article primarily discusses class action lawsuits involving various companies, but it highlights that Moderna's (MRNA) stock rose by 2.57% due to speculation regarding its collaboration with Metagenomi, which is mentioned in legal filings. The increase in Moderna's stock is likely related to investor confidence stemming from ongoing developments in its collaborations and potential business prospects.
	2024-10-10	-3.45 %
Moderna (MRNA) stock fell by 3.45% following Cadinha & Co. LLC's significant reduction of its holdings in the company by 96.3% during the third quarter, indicating a loss of confidence or a shift in investment strategy that may have influenced market perception. Moderna (MRNA) stock declined by 3.45%, reaching a new 52-week low of $57.32 due to ongoing investor concerns and possibly unfavorable analyst ratings changes related to the company's performance. The Moderna (MRNA) stock fell by 3.45% likely due to the termination of its collaboration with Metagenomi on developing treatments for primary hyperoxaluria type 1 (PH1), which caused a negative market reaction.
	2024-10-09	+0.8 %
Moderna (MRNA) stock experienced a 0.8% increase following the announcement of a class action lawsuit against Metagenomi, which involved a significant collaboration with Moderna that was terminated, leading to investor speculation about the implications for both companies. The rise in Moderna's stock may be attributed to the heightened investor interest and the perceived stability or potential in Moderna's ongoing projects as Metagenomi's issues draw attention. Moderna (MRNA) stock rose 0.8% after CFO James M. Mock sold 715 shares, indicating investor confidence despite insider selling. The article discusses a class-action lawsuit related to Metagenomi, Inc. and highlights the upcoming deadline for investors to file a lead plaintiff motion, but also notes that Moderna (MRNA) stock rose by 0.8% likely due to positive investor sentiment stemming from its collaborations and market positioning, independent of the Metagenomi situation.
	2024-10-08	-0.56 %
Moderna (MRNA) stock declined by 0.56% following CFO James M. Mock's sale of 715 shares, which may have raised concerns among investors about insider selling. The article discusses a podcast interview with Vince Aita of Cutter Capital, who shares his journey from academia to finance and offers insights on biotech investing, but notes that Moderna (MRNA) stock recently experienced a decline of 0.56%. The drop in Moderna (MRNA) stock could be attributed to various factors, including market reactions to biotech sector trends, investor sentiment, or company-specific news that may have raised concerns about its future performance or financial stability. The Moderna (MRNA) stock declined by 0.56% due to allegations of misleading statements regarding the effectiveness of its respiratory syncytial virus vaccine, mRNA-1345, which overstated its clinical and commercial prospects. Moderna (MRNA) stock fell by 0.56% amid allegations that Metagenomi Inc. misled investors about its collaboration with Moderna, which was terminated shortly after Metagenomi's IPO, leading to a decline in confidence regarding both companies. Moderna (MRNA) stock fell by 0.56% due to concerns over a terminated collaboration agreement with Metagenomi, which impacted investor confidence in both companies' future prospects.
	2024-10-07	-2.46 %
The article highlights the need for Europe to adopt new economic policies to foster innovation, as its current inability to do so has led to a stagnation in growth compared to the United States. Moderna (MRNA) stock declined by -2.46% due to broader market conditions affecting biotechnology stocks, concerns about future revenue as COVID-19 vaccine demand wanes, or potential investor sentiment regarding profitability and innovation outlook in the sector. Moderna (MRNA) stock declined by 2.46% amid concerns arising from a securities class action lawsuit against Metagenomi, which alleges misrepresentations related to its collaboration with Moderna. Moderna (MRNA) stock fell by 2.46% following news that Metagenomi announced the termination of its collaboration agreement with the company, leading to investor concerns regarding the implications for future revenue and partnerships. Moderna (MRNA) stock fell by 2.46% after Sanctuary Advisors LLC disclosed its acquisition of a new stake in the company, which may indicate investor uncertainty or market reaction to changes in institutional ownership.
	2024-10-04	-1.42 %
The article discusses a class action lawsuit involving Metagenomi, Inc., which is linked to Moderna due to their previous collaboration that was terminated, likely contributing to a decline in Moderna's stock price by 1.42%. The stock decline may be attributed to investor concerns regarding the fallout from the termination of the collaboration between Metagenomi and Moderna, which could negatively impact investor perceptions of Moderna's future prospects. Moderna's stock (MRNA) fell by 1.42% after Dana Investment Advisors Inc. significantly reduced its stake in the company by 75.6% in the second quarter. Moderna (MRNA) stock fell by 1.42% amid heightened competition in the weight-loss drug market, with emerging players like Viking Therapeutics stirring investor focus away from established giants including Pfizer, who are struggling to keep pace with quicker-moving rivals in this rapidly expanding sector. Moderna (MRNA) stock declined by 1.42% likely due to market reactions to updates and competition among COVID-19 vaccines, as well as concerns regarding vaccine efficacy and public interest in vaccinations. Moderna (MRNA) stock declined by 1.42% largely due to market reactions following the termination of its collaboration with Metagenomi, which was disclosed shortly after Metagenomi's IPO, leading to concerns about the financial prospects of both companies. Moderna (MRNA) stock experienced a decline of 1.42% due to concerns stemming from a class action lawsuit against Metagenomi, which revealed that their collaboration with Moderna would be ceasing, leading to doubts about the company's future business prospects.
	2024-10-03	-3.31 %
Moderna, Inc. (NASDAQ: MRNA) shares fell to a new 52-week low, closing down 3.31% at $62.24, due to a lack of investor confidence and analysts potentially downgrading their outlook on the stock. Moderna (MRNA) stock fell by 3.31%, attributed to growing scrutiny over questionable advertising practices that downplayed the risks associated with COVID-19 vaccines and leveraged regulatory loopholes, amidst legal accusations and potential implications for the efficacy and marketing of their products. Moderna (MRNA) stock experienced a decline of 3.31% due to concerns regarding its marketing practices and the impact of ongoing legal scrutiny over misleading COVID-19 vaccine advertisements, which may undermine public confidence and regulatory integrity in the pharmaceutical industry. Moderna (MRNA) stock fell by 3.31% after Marshall Wace LLP reported a significant increase in its stake in the company, indicating potential volatility or market adjustments following the announcement.
	2024-10-02	-1.2 %
Moderna (MRNA) stock dropped by 1.2% following the announcement of a class action lawsuit alleging that the company misrepresented the effectiveness of its mRNA-1345 respiratory syncytial virus vaccine, leading investors to have inflated expectations of its clinical and commercial potential. Moderna (MRNA) stock fell 1.2% due to the company providing a weak sales outlook for 2025 and cutting its research and development budget for 2027. Moderna (MRNA) stock declined by 1.2% due to concerns arising from the termination of its collaboration agreement with Metagenomi, a relationship that was previously viewed as pivotal for both companies' developments in genetic medicines. Moderna (MRNA) stock declined by 1.2% as the arrival of the respiratory virus season in the U.S. and the increased availability of vaccines for Covid-19, flu, and RSV raise concerns about the effectiveness and uptake of these vaccines, potentially impacting future revenues for vaccine manufacturers like Moderna.
	2024-10-01	-4.34 %
Moderna (MRNA) stock fell by 4.34% after a class action lawsuit was filed alleging that the company misled investors about the effectiveness and prospects of its mRNA-1345 treatment, which were overstated, leading to significant investor losses. Moderna (MRNA) stock fell by 4.34% likely due to competitive pressures in oncology from Pfizer, as the two companies are now pursuing similar cancer treatment avenues using mRNA technology, raising concerns about Moderna's unique position in the market. Moderna (MRNA) stock fell by 4.34% following the announcement that Ariadne Wealth Management LP acquired a new stake in the company, which may have raised concerns among investors about market sentiment or potential dilution.
	2024-09-30	+1.64 %
The article discusses a class action securities lawsuit against Metagenomi, Inc. concerning alleged securities fraud related to its collaboration with Moderna, which may have positively impacted Moderna's (MRNA) stock by instilling investor confidence amidst the uncertainty surrounding Metagenomi's future. Moderna's stock likely went up due to a perception of resilience and potential for continued innovation in the face of challenges faced by its collaborators, as well as general market movements favorable to biotech stocks. Moderna (MRNA) stock rose by 1.64% amidst a generally positive market environment, with significant gains across major indices and strong sector performances, indicating heightened investor confidence and interest in biotechnology and healthcare as part of the overall market rally. Moderna (MRNA) stock rose 1.64% following Susquehanna Fundamental Investments LLC's announcement of acquiring a new stake in the company during the second quarter. The article discusses an investigation by Faruqi & Faruqi LLP into Metagenomi, Inc. due to allegations of misleading statements regarding its partnership with Moderna, which may have influenced investor sentiment. Moderna (MRNA) stock likely went up by 1.64% as positive investor sentiment could have been driven by changes in the market dynamics following the news related to Metagenomi, as investors reassessed Moderna's standing after the collaboration termination was highlighted.
	2024-09-27	+2.85 %
Moderna (MRNA) stock rose by 2.85% amid ongoing legal issues related to Metagenomi Inc., including allegations that Metagenomi misled investors about its collaboration with Moderna which was recently terminated, potentially stabilizing investor sentiment in the biotech sector. The article discusses a class action lawsuit filed against Metagenomi Inc., alleging issues with its collaboration with Moderna, which negatively impacted Metagenomi's stock, while also noting that Moderna (MRNA) stock rose by 2.85% likely due to investor confidence bolstered by its ongoing role in developing genetic therapies, despite Metagenomi's challenges. The article discusses a class action lawsuit against Metagenomi, Inc. regarding its initial public offering and its collaboration with Moderna, which may indirectly impact Moderna's stock price positively by clarifying its business relationships and reducing investor uncertainty. Modern's stock (MRNA) likely went up by 2.85% due to positive investor sentiment or market reactions to their ongoing business developments, possibly linked to the highlighted partnership or litigation news surrounding Metagenomi. The article discusses a securities class action lawsuit filed against Metagenomi, Inc. surrounding misrepresentations about its collaboration with Moderna, which might have contributed to a rise in Moderna's stock by 2.85% due to investor optimism or confidence stemming from the legal developments associated with its partnership.
	2024-09-26	+0.46 %
The recent 0.46% rise in Moderna (MRNA) stock is partly attributed to the positive implications of Novo Nordisk's $600 million partnership with NanoVation, which focuses on lipid nanoparticle (LNP) technology and gene editing therapies that could enhance the company's drug delivery methods, reminiscent of Moderna's successful COVID-19 vaccine strategy. Moderna (MRNA) stock increased by 0.46% following the announcement of class action lawsuits alleging that the company made misleading statements about its mRNA-1345 product's effectiveness, which may have led to a temporary uptick in investor sentiment or speculation about the stock's potential future performance amid these legal developments.
	2024-09-25	-0.47 %
Moderna (MRNA) stock fell by 0.47% amid rising concerns about a new surge in COVID-19 cases and the potential for renewed public health restrictions as the pandemic resurfaces, which may impact vaccine uptake and overall market sentiment towards biopharmaceutical companies. Moderna's (MRNA) stock dipped by 0.47% as Ensign Peak Advisors significantly reduced its holdings in the company by 52.3%, indicating possible decreased confidence from institutional investors.
	2024-09-24	-0.31 %
Moderna (MRNA) stock fell by 0.31% after Renaissance Technologies LLC reduced its stake in the company by 20.3% during the second quarter, indicating potential reduced investor confidence.
	2024-09-23	-2.36 %
Moderna (MRNA) stock fell by 2.36% as the post-pandemic demand for their coronavirus vaccine has diminished, impacting their market performance. Moderna (MRNA) stock fell by 2.36% due to the company's announcement of a delayed break-even projection, now expected in 2028 instead of 2026, and a decision to reduce its R&D expenses by approximately $1.1 billion by 2027, which investors interpreted as a negative sign for its future growth potential.
	2024-09-20	-3.43 %
Moderna (MRNA) stock fell by 3.43% due to broader market concerns influenced by ongoing events such as strikes, earnings reports, and performance from other major companies. Moderna Inc. (NASDAQ:MRNA) stock declined by -3.43% due to disappointment over its progress in developing a personalized vaccine despite having substantial funding, leading analysts to question its momentum compared to other stocks focused on artificial intelligence, which currently capturing market interest. Moderna's (NASDAQ: MRNA) stock has declined due to a 13% drop following the announcement of significant cost cuts that will impact its pipeline and delay profitability for several years. Moderna (MRNA) stock fell by 3.43% following positive trial data presented by Pfizer for its experimental cancer treatment, which may enhance Pfizer's competitive position in the oncology market and overshadow Moderna's upcoming cancer vaccine developments. Moderna (MRNA) stock fell by 3.43% due to a combination of factors including broader market concerns, negative investor sentiment, and possible impacts from ongoing developments in the pharmaceutical and biotechnology sectors.
	2024-09-19	-2.63 %
Moderna (MRNA) stock fell by 2.63% following Novo Nordisk's announcement of a substantial $530 million drug-development collaboration with Korro Bio, which focuses on RNA editing, a field that overlaps with Moderna's interests in mRNA technology, raising concerns about increased competition in biopharma.
	2024-09-18	-2.96 %
Moderna (MRNA) stock fell by 10% after the company announced significant cost cuts of $1.1 billion amid declining sales in its COVID-19 vaccine business and plans to develop 10 new products by 2027. The decline was attributed to efforts to navigate these challenges during a period of slowing demand for its vaccines. Moderna (MRNA) stock fell by 2.96% primarily due to the initiation of class action lawsuits alleging that the company made false and misleading statements regarding the efficacy of its mRNA-1345 product, which has raised concerns about the company's operations and future prospects. Moderna (MRNA) stock fell by 2.96% due to a class action lawsuit alleging the company misled investors about the efficacy of its RSV vaccine, mRNA-1345, which was claimed to be less effective than previously represented.
	2024-09-17	+4.08 %
Moderna (MRNA) stock rose by 4.1% after health regulators in Canada approved an updated COVID-19 vaccine for fall immunization campaigns, contributing to positive sentiment in the market. Moderna (MRNA) stock rose 4.08% after Canadian regulators approved the company's updated COVID-19 vaccine, Spikevax KP.2, for individuals aged six months and older, following similar approval from the U.S. FDA. The increase in stock price is primarily due to the positive regulatory news regarding the new vaccine's authorization, signaling future revenue potential for the company. Moderna (MRNA) stock increased by 4.08% last night, possibly due to positive market sentiment or analyst commentary, despite being noted as a disappointment in the past.
	2024-09-16	+1.3 %
Moderna (MRNA) stock rose by 1.3% due to positive investor sentiment linked to the Federal Reserve's anticipated rate cuts and the overall market outlook, which suggests favorable conditions for investments in technology and healthcare sectors, including biotech. Moderna (MRNA) stock experienced a 1.3% increase, likely influenced by investor optimism surrounding the general positive momentum in the biotechnology sector, particularly following JPMorgan's upgrade of BioNTech (BNTX) amid encouraging data from its oncology pipeline, which parallels themes of diversification and growth that also apply to Moderna. Moderna (MRNA) stock increased by 1.3% due to rising COVID-19 levels and the approach of flu season, which is driving demand for updated respiratory virus vaccines, including those provided by Moderna. Moderna (MRNA) stock rose by 1.3% amid rising Covid-19 levels in the United States and an approaching respiratory disease season, as the demand for updated Covid-19 vaccines from Moderna and Pfizer increases to help combat the circulating variants. The stock's increase is likely due to the anticipation of higher vaccine uptake as public health officials stress the importance of vaccination to mitigate the impact of upcoming respiratory illnesses, including Covid-19, flu, and RSV.
	2024-09-13	-2.01 %
Moderna (MRNA) stock fell 2.01% after analysts downgraded their ratings due to the company's delayed profitability target and lower revenue expectations, indicating potential challenges in raising capital to meet its new guidance amidst declining demand for COVID-19 vaccines. Moderna (MRNA) stock decreased by 2.01% as the company has faced declining demand for its COVID-19 vaccine, resulting in an over 80% drop from its peak in 2021, despite having potential growth in its vaccine pipeline and other product developments. Moderna (MRNA) stock fell by 2.01% due to broader market trends and possibly investor reactions to recent news surrounding the company and its competitors. Moderna's (MRNA) stock dropped by 2.01% due to broader market fluctuations and specific investor concerns affecting its performance on the day. Moderna (MRNA) stock declined by 2.01% after JPMorgan downgraded it due to the company's announcement of significant cuts to its research and development budget. Moderna (MRNA) stock declined by 2.01% due to a series of downgrades and reduced price targets following disappointing updates presented during its Research & Development Day. Moderna (MRNA) stock declined by 2.01% after the company announced significant cuts to its research and development budget and received a downgraded rating from JPMorgan, leading to concerns about its future profitability and project approvals. The stock's decline is attributed to the project cancelation and reduced revenue forecasts, reflecting a less optimistic outlook for the company's mRNA platform and research pipeline. Moderna (MRNA) stock fell by 2.01% after Brookline Capital Markets revised its price target down from $310 to $238 following an update on the company's product pipeline that revealed lower projected revenues and profitability timelines due to changes in project prioritization and discontinued programs.
	2024-09-12	-12.36 %
Moderna (MRNA) stock fell over 18% due to the company's announcement of a $1.1 billion reduction in its research and development budget, as part of a strategy to prioritize its existing product pipeline and focus on commercial growth, raising investor concerns about the future of new product development. Moderna (MRNA) stock fell by 12.36% primarily due to the company's decision to significantly cut expenses by $1.1 billion by 2027, which involves reducing research and development spending and pausing or scrapping some of its pipeline products, following a decline in its COVID business. The article reports that Moderna's (MRNA) stock fell by 12.36% due to negative market sentiment and concerns affecting the biotech sector, including potential issues with vaccine demand and broader economic factors. Moderna (MRNA) stock fell by over 12% in pre-market trading due to the company's announcement of cost-cutting measures and a focus on narrowing its research and development efforts, prompting concerns about future growth and revenue projections. Moderna (MRNA) stock dropped 12.36% after the company lowered its annual revenue outlook for 2025 and announced cuts to its annual research and development budget. Moderna (MRNA) stock fell by 11.9% after the company announced it now expects to break even in 2028, which is later than its previous prediction of 2026. Moderna (MRNA) stock plummeted 12.4% after the company announced a delayed timeline for breaking even on profits until 2028, along with a significant reduction in its research and development spending. Moderna (MRNA) stock fell by 12.36% due to notable declines in the market, contrasting with the upward movements of other stocks like Nvidia and Avago Technologies.
	2024-09-11	+0.29 %
Moderna (MRNA) stock saw a slight increase of 0.29% due to positive developments in the biotechnology sector and FDA approvals for updated COVID-19 vaccines targeting newer variants, reflecting a favorable market sentiment toward the company amidst ongoing innovations in its product offerings.
	2024-09-10	+3.49 %
Moderna (MRNA) stock increased by 3.49% amid ongoing class action lawsuits alleging that the company made misleading statements regarding the effectiveness and prospects of its mRNA-1345 product; the rise may be attributed to investor optimism or speculation regarding the outcome of these legal actions. The article discusses a notice from The Gross Law Firm regarding a class action lawsuit against Moderna, Inc. (MRNA), which has seen its stock rise by 3.49% due to a potential recovery opportunity for shareholders from alleged misleading statements about its respiratory syncytial virus vaccine, mRNA-1345.
	2024-09-09	+5.1 %
Moderna's stock (MRNA) rose 5.1% following the announcement that its Laval, Quebec manufacturing facility received a Drug Establishment License from Health Canada, certifying its compliance with safety and quality standards for drug production. Moderna (MRNA) stock rose 5.1% following the receipt of a Drug Establishment License from Health Canada for its manufacturing facility in Laval, Quebec, which confirms its compliance with safety and quality standards for producing drug substances.
	2024-09-06	-0.75 %
Moderna (MRNA) stock fell by 1.39% despite positive results from animal studies indicating that its mRNA-1769 vaccine for mpox showed greater efficacy than the current Jynneos vaccine; the decline may be attributed to overall market fluctuations and investor reactions to recent performance rather than the vaccine's promising results. Moderna's (MRNA) stock fell by 0.75% amid concerns that provinces in Canada must destroy their existing XBB COVID-19 vaccine supplies before receiving new fall booster shots targeting newer variants, which has led to a halt in vaccination campaigns and uncertainty about the vaccine distribution timeline. Moderna (MRNA) stock fell by 0.75% due to uncertainty among pediatricians regarding the demand for COVID vaccines as many are hesitant to order large quantities, fearing wastage and financial risks associated with the low uptake rates among eligible children, which has led to a reduced forecast for vaccine administration.
	2024-09-05	+1.31 %
Moderna (MRNA) stock rose by 1.31% following news of a class action lawsuit against the company regarding allegations that it misled investors about the efficacy of its RSV vaccine, mRNA-1345, which may indicate optimism about its future or resolution of related uncertainties. The stock increase might be attributed to investor sentiment reacting positively to the developments or recent performance indicators, despite the underlying legal issues. Moderna (MRNA) stock rose 1.31% due to the FDA's approval of updated vaccines amid a surge in COVID-19 infections, coinciding with the end of the federal Bridge Access program, which will require millions of uninsured Americans to pay out-of-pocket for vaccines. Moderna's (MRNA) stock rose 1.31% after early testing showed that its mRNA mpox vaccine surpasses licensed competitors in alleviating symptoms and potentially reducing transmission, indicating its potential to expand beyond the Covid-19 market. Additionally, Nichole Wischoff has successfully raised $50 million for Wischoff Ventures to invest in over 30 startups, primarily in fintech, logistics, and manufacturing.
	2024-09-04	-0.62 %
Moderna (MRNA) stock fell by 0.62% amidst increased competition from Novavax's newly authorized COVID vaccine, which adds options for consumers alongside Moderna's own updated mRNA vaccines, reflecting the ongoing adaptation of the market in response to evolving COVID treatment strategies. Moderna (MRNA) stock recently declined by 0.62%, partially due to the Chief Legal Officer's stock sale related to tax obligations and ongoing concerns about the company's significant revenue decline, executive transactions, and cautious analyst outlooks on future sales and profitability. Moderna (MRNA) stock declined by 0.62% due to ongoing class action lawsuits alleging that the company made materially false and misleading statements about the effectiveness and commercial prospects of its mRNA-1345 product. Moderna's (MRNA) stock fell by 0.62% primarily due to concerns about low demand for COVID-19 vaccines, as pediatricians across the U.S. are scaling back orders in anticipation of parents' waning interest following a recent trend of underwhelming vaccination rates among eligible children. Moderna (MRNA) stock fell by 0.62% due to concerns over the company's financial performance and ongoing losses, suggesting a need for operational improvements to stabilize its profitability. Moderna (MRNA) stock has declined by 0.62% following the FDA's authorization of a new COVID-19 vaccine from Novavax, providing an alternative to its and Pfizer's vaccines, which may lead to reduced demand for Moderna's products. Moderna (MRNA) stock declined by 0.62% likely due to market reactions to developments in the COVID-19 vaccine landscape, including updated vaccine approvals and increased competition from other companies like Pfizer and Sunshine Biopharma, which are also advancing their COVID-19 treatments.
	2024-09-03	-5.76 %
Moderna (MRNA) stock declined by 5.76% following the FDA's Emergency Use Authorization of Novavax's COVID-19 vaccine, which may have raised concerns about increased competition in the COVID vaccine market.
	2024-08-30	-0.24 %
Moderna (MRNA) stock decreased by 0.24% after Chief Financial Officer James M. Mock sold shares for tax obligations, alongside mixed analyst reviews following a revision of the company's 2024 revenue outlook and overall weaker performance expectations for its COVID-19 vaccines and other products. Moderna (MRNA) stock, along with other underperformers like Intel and Dollar General, experienced a decline of -0.24% as it became one of the biggest losers in the S&P 500 for the month, likely due to overall market trends and investor sentiment impacting the biotech sector. Moderna (MRNA) stock declined by 0.24% amidst announcements that the Sinovac-CoronaVac vaccine will be discontinued in Singapore, as it was not applied for full registration, prompting a shift towards fully registered vaccines like Moderna's mRNA vaccine for Covid-19. The drop in stock may stem from investors reacting to the broader context of vaccine strategies and demand for Covid-19 vaccinations in Singapore, which could impact future sales and revenue projections for Moderna.

1
500 / page